SUPN241220P27000
- 0.00
- 0.000.00%
Supernus Pharmaceuticals Newsroom
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Supernus Pharmaceuticals (SUPN) and Skye Bioscience (SKYE)
Piper Sandler Sticks to Their Hold Rating for Supernus Pharmaceuticals (SUPN)
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
A Quick Look at Today's Ratings for Supernus Pharmaceuticals(SUPN.US), With a Forecast Between $36 to $43
A Quick Look at Today's Ratings for Supernus Pharmaceuticals(SUPN.US), With a Forecast Between $36 to $43
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN) and Tyra Bioscience (TYRA)
Supernus Pharmaceuticals (SUPN) Gets a Buy From TD Cowen
Piper Sandler Sticks to Their Hold Rating for Supernus Pharmaceuticals (SUPN)
Jefferies Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Cuts Target Price to $40
Jefferies Issues a Buy Rating on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Analyst Ratings
Piper Sandler Downgrades Supernus Pharmaceuticals(SUPN.US) to Hold Rating, Cuts Target Price to $36
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Strong Buy Rating for Supernus Pharmaceuticals Amidst Robust Revenue Growth and Qelbree's Market Success
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)